The Department of Defense Pharmacy & Therapeutics Committee's mission is to uniformly, consistently, and equitably provide appropriate drug therapy to meet the clinical needs of DOD beneficiaries in an effective, efficient, and fiscally responsible manner.
To learn more, please see the December 2004 Health Affairs Policy 04-032, TRICARE Pharmacy Benefit Formulary Management (clarified Mar. 22, 2005).
DOD P&T Committee Meeting Schedule
View DOD P&T Meeting Minutes See Archived Meeting Pages
Aug. 2-3, 2023
Uniform Formulary Request for Quote Information
- UF BPA & UF ADP RFQ Documents Posted: April 20, 2023
- Pre-Proposal Teleconference: May 10, 2023 at 1 p.m. CT
- UF BPA & UF ADP Class Quotes Due: June 15, 2023 at 12 p.m. CT
*Please note that all agents in the class, including brands and all generics, may be considered for formulary management actions. Additionally, if a drug is approved prior to Aug. 27, 2015, but not currently available the committee may still make a formulary recommendation.
| Class Review |
Designated Newly Approved Drugs |
Drugs in Previously Reviewed Classes |
- LUTEINIZING HORMONE-RELEASING HORMONE AGONISTS-ANTAGONISTS - PROSTATE CANCER AGENTS:
- LUTEINIZING HORMONE-RELEASING HORMONE AGONISTS-ANTAGONISTS - CENTRAL PRECOCIOUS PUBERTY AGENTS:
- LUTEINIZING HORMONE-RELEASING HORMONE AGONISTS-ANTAGONISTS - ENDOMETRIOSIS/FIBROIDS AGENTS:
- WHITE BLOOD CELL STIMULANTS - FILGRASTIM:
- Granix
-
Neupogen
-
Nivestym
-
Releuko
- WHITE BLOOD CELL STIMULANTS - PEGFILGRASTIM:
- Fulphila
- Fylnetra
- Neulasta
- Neulasta Onpro
- Nyvepria
- Stimufend
- Udenyca
- Ziextenzo
|
|
|
May 3-4, 2023
Uniform Formulary Request for Quote Information
- UF BPA & UF ADP RFQ Documents Posted: Jan. 27, 2023
- Pre-Proposal Teleconference: Feb. 1, 2023 at 1 p.m. CT
- UF BPA & UF ADP Class Quotes Due: March 20, 2023 at 12 p.m. CT
*Please note that all agents in the class, including brands and all generics, may be considered for formulary management actions. Additionally, if a drug is approved prior to Aug. 27, 2015, but not currently available the committee may still make a formulary recommendation.
| Class Review |
Designated Newly Approved Drugs |
Drugs in Previously Reviewed Classes |
- ANTILIPIDEMICS-1 - PCSK9:
- OPHTHALMIC - DRY EYE:
-
Cequa
-
Eysuvis
-
Restasis
-
Tyrvaya
-
Xiidra
-
Verkazia
|
-
Amjevita
-
Altuviiio
-
Atorvaliq
-
Daybue
-
Filspari
-
Jaypirca
-
Konvomep
-
Krazati
-
Orserdu
-
Pradaxa Pellets
-
Rezvoglar
-
Stimufend
-
Tezspire
|
|
Feb. 8-9, 2023
Uniform Formulary Request for Quote Information (Class Nephrology Misc.)
- UF BPA & UF ADP RFQ Documents Posted: Dec. 2, 2022
- Pre-Proposal Teleconference: Dec. 7, 2022 at 1 p.m. CT
- UF BPA & UF ADP Class Quotes Due: Jan. 20, 2023 at 12 p.m. CT
Uniform Formulary Request for Quote Information (Class Androgens Anabolic Steroids and Sleep Disorders)
- UF BPA & UF ADP RFQ Documents Posted: Oct. 24, 2022
- Pre-Proposal Teleconference: Nov. 9, 2022 at 1 p.m. CT
- UF BPA & UF ADP Class Quotes Due: Dec. 14, 2022 at 12 p.m. CT
*Please note that all agents in the class, including brands and all generics, may be considered for formulary management actions. Additionally, if a drug is approved prior to Aug. 27, 2015, but not currently available the committee may still make a formulary recommendation.
| Class Review |
Designated Newly Approved Drugs |
Drugs in Previously Reviewed Classes |
- ANDROGENS-ANABOLIC STEROIDS - TESTOSTERONE REPLACEMENT THERAPIES:
- Androderm
- Jatenzo
- Kyzatrex
- Methitest
- Natesto
- Testim
- Testred
- Tlando
- Xyosted
- SLEEP DISORDERS - DUAL OREXIN RECEPTOR ANTAGONISTS:
- NEPHROLOGY AGENTS MISCELLANEOUS – NA:
|
-
Auvelity
-
Basaglar Tempo Pen
-
Ermeza
-
Furoscix
-
Fylnetra
-
Humalog Tempo Pen
-
Leuprolide Depot
-
Lytgobi
-
Lyumjev Tempo Pen
-
Noxafil
-
Relyvrio
-
Rezlidhia
-
Xelstrym
|
|
If the DOD P&T Committee is unable to complete an evaluation of any of the drug classes, the Committee will continue its efforts at the next meeting.
Subject to Change Disclaimer
The Defense Health Agency reserves the right to change the classes, sub-classes and/or designated new drugs, and other requirements, of whatever kind, affecting solicitations. The provisions of this table do not constitute a contract, express or implied, between the DHA and manufacturer or eligible bidder.